GT200100190A - 7-oxo-piridopirimidinas - Google Patents
7-oxo-piridopirimidinasInfo
- Publication number
- GT200100190A GT200100190A GT200100190A GT200100190A GT200100190A GT 200100190 A GT200100190 A GT 200100190A GT 200100190 A GT200100190 A GT 200100190A GT 200100190 A GT200100190 A GT 200100190A GT 200100190 A GT200100190 A GT 200100190A
- Authority
- GT
- Guatemala
- Prior art keywords
- dermatitis
- pyridopirimidinas
- oxo
- pyridopirimidines
- infetions
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 abstract 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229940072885 atopica Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22957700P | 2000-08-31 | 2000-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200100190A true GT200100190A (es) | 2002-05-23 |
Family
ID=22861834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200100190A GT200100190A (es) | 2000-08-31 | 2001-09-18 | 7-oxo-piridopirimidinas |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1315727B1 (enExample) |
| JP (1) | JP4146721B2 (enExample) |
| KR (1) | KR100582325B1 (enExample) |
| CN (2) | CN100358892C (enExample) |
| AR (1) | AR033996A1 (enExample) |
| AT (1) | ATE298751T1 (enExample) |
| AU (2) | AU2002212147B2 (enExample) |
| BR (1) | BR0113590A (enExample) |
| CA (1) | CA2420122A1 (enExample) |
| DE (1) | DE60111752T2 (enExample) |
| ES (1) | ES2243568T3 (enExample) |
| GT (1) | GT200100190A (enExample) |
| MX (1) | MXPA03001733A (enExample) |
| PA (1) | PA8527401A1 (enExample) |
| PE (1) | PE20020524A1 (enExample) |
| UY (1) | UY26920A1 (enExample) |
| WO (1) | WO2002018379A2 (enExample) |
| ZA (1) | ZA200301078B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04010267A (es) * | 2002-04-19 | 2005-02-03 | Smithkline Beecham Corp | Compuestos novedosos. |
| ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
| DE602004024536D1 (de) * | 2003-07-07 | 2010-01-21 | Van Andel Res Inst | Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors |
| WO2005105097A2 (en) * | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| BRPI0512046A (pt) * | 2004-06-15 | 2008-02-06 | Pfizer | derivados de ácido benzimidazolona carboxìlico |
| US20090306380A1 (en) * | 2005-04-25 | 2009-12-10 | Shigeyoshi Nishino | Process for preparing 4-amino-2-alkylthio-5-pyrimidinecarbaldehyde |
| JP2006321749A (ja) * | 2005-05-19 | 2006-11-30 | Ube Ind Ltd | ２−シアノマロンアルデヒドのアルカリ金属塩の製法 |
| ES2329419T3 (es) | 2006-01-31 | 2009-11-25 | F. Hoffmann-La Roche Ag | 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas. |
| JP2010509265A (ja) | 2006-11-09 | 2010-03-25 | エフ．ホフマン−ラ ロシュ アーゲー | キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法 |
| CA2690327A1 (en) | 2007-06-15 | 2008-12-18 | Thomas P. Cleary | A novel process for the preparation of 3-amino-pentan-1,5-diol |
| CA2776770A1 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| US20120184542A1 (en) | 2011-01-19 | 2012-07-19 | Kevin Anderson | Pyrido pyrimidines |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
| AU2019338992B2 (en) * | 2018-09-14 | 2022-01-20 | Abbisko Therapeutics Co., Ltd. | FGFR inhibitor, preparation method therefor and application thereof |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6183168A (ja) * | 1984-09-28 | 1986-04-26 | Ube Ind Ltd | ２−メルカプト−４−アミノ−５−ホルミルピリミジンおよびその製法 |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| WO1997044321A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| CA2420286A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
-
2001
- 2001-08-22 CN CNB018150276A patent/CN100358892C/zh not_active Expired - Fee Related
- 2001-08-22 EP EP01980258A patent/EP1315727B1/en not_active Expired - Lifetime
- 2001-08-22 BR BR0113590-2A patent/BR0113590A/pt not_active Application Discontinuation
- 2001-08-22 DE DE60111752T patent/DE60111752T2/de not_active Expired - Fee Related
- 2001-08-22 AU AU2002212147A patent/AU2002212147B2/en not_active Ceased
- 2001-08-22 AU AU1214702A patent/AU1214702A/xx active Pending
- 2001-08-22 MX MXPA03001733A patent/MXPA03001733A/es active IP Right Grant
- 2001-08-22 KR KR1020037002955A patent/KR100582325B1/ko not_active Expired - Fee Related
- 2001-08-22 CN CNB2005100835295A patent/CN1303072C/zh not_active Expired - Fee Related
- 2001-08-22 CA CA002420122A patent/CA2420122A1/en not_active Abandoned
- 2001-08-22 AT AT01980258T patent/ATE298751T1/de not_active IP Right Cessation
- 2001-08-22 JP JP2002523894A patent/JP4146721B2/ja not_active Expired - Fee Related
- 2001-08-22 WO PCT/EP2001/009688 patent/WO2002018379A2/en not_active Ceased
- 2001-08-22 ES ES01980258T patent/ES2243568T3/es not_active Expired - Lifetime
- 2001-08-28 PA PA20018527401A patent/PA8527401A1/es unknown
- 2001-08-28 PE PE2001000861A patent/PE20020524A1/es not_active Application Discontinuation
- 2001-08-30 AR ARP010104131A patent/AR033996A1/es unknown
- 2001-08-30 UY UY26920A patent/UY26920A1/es not_active Application Discontinuation
- 2001-09-18 GT GT200100190A patent/GT200100190A/es unknown
-
2003
- 2003-02-07 ZA ZA200301078A patent/ZA200301078B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2243568T3 (es) | 2005-12-01 |
| AU1214702A (en) | 2002-03-13 |
| CA2420122A1 (en) | 2002-03-07 |
| CN100358892C (zh) | 2008-01-02 |
| WO2002018379A3 (en) | 2002-07-25 |
| AR033996A1 (es) | 2004-01-21 |
| EP1315727A2 (en) | 2003-06-04 |
| MXPA03001733A (es) | 2003-05-27 |
| PA8527401A1 (es) | 2002-07-30 |
| ZA200301078B (en) | 2004-05-07 |
| EP1315727B1 (en) | 2005-06-29 |
| CN1721412A (zh) | 2006-01-18 |
| JP2004507540A (ja) | 2004-03-11 |
| DE60111752T2 (de) | 2006-05-04 |
| AU2002212147B2 (en) | 2007-10-18 |
| CN1303072C (zh) | 2007-03-07 |
| KR20030022423A (ko) | 2003-03-15 |
| DE60111752D1 (de) | 2005-08-04 |
| BR0113590A (pt) | 2003-07-22 |
| UY26920A1 (es) | 2002-02-28 |
| PE20020524A1 (es) | 2002-06-18 |
| JP4146721B2 (ja) | 2008-09-10 |
| CN1451004A (zh) | 2003-10-22 |
| ATE298751T1 (de) | 2005-07-15 |
| KR100582325B1 (ko) | 2006-05-22 |
| WO2002018379A2 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200100190A (es) | 7-oxo-piridopirimidinas | |
| HN2002000136A (es) | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis | |
| CR7069A (es) | Derivados de pirazol para el tratamiento de vih | |
| PA8539201A1 (es) | Pirido-pirimidinas 6-sustituidas | |
| CO4180606A1 (es) | Compuestos de isoxazolina como agentes antiinflamatorios | |
| CL2004000626A1 (es) | Compuestos derivados de bencenosulfonamida, sus sales; composicion farmaceutica, y su uso en el tratamiento de una enfermedad relacionada con ccr3, tales como asma, dermatitis atopica, rinitis, vih, granuloma pulmonar, alzheimer. | |
| ECSP055801A (es) | Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas | |
| PA8804701A1 (es) | Nucleosidos 2'4'-sustituidos como agentes antivirales | |
| ES2139754T3 (es) | 3-fenil-2-isoxazolinas como agentes antiinflamatorios. | |
| ECSP045003A (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos. | |
| HN2004000146A (es) | Dihidroquinazolinas sustituidas | |
| UY26598A1 (es) | Moduladores de los receptores de la adenosina | |
| MX2019002904A (es) | Composiciones de arn de alta pureza y métodos para su preparación. | |
| BR0306922A (pt) | N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina | |
| AR034259A1 (es) | Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen | |
| BR0110246A (pt) | Amidas de ácido benzóico substituìdas e uso das mesmas para inibição de angiogênese | |
| BR0112063A (pt) | Derivados de 5,6-dihidro-pirona substituìdos por fenila como pesticidas e herbicidas | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| UY26544A1 (es) | Antagonistas del factor liberador de corticotropina. | |
| GT200500007A (es) | [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia. | |
| BRPI0415209A (pt) | derivados de tetraidronaftaleno, processo para a produção deles e seu emprego como agentes antiinflamatórios | |
| HN2002000332A (es) | Sales de acido succinico de 5,7,14 triazatetraciclo (10. 3.1.02.11.04,9)-hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
| BRPI0315644B8 (pt) | compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos | |
| CL2011003144A1 (es) | Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05). | |
| CO5611124A2 (es) | Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos |